The stock of Acumen Pharmaceuticals Inc (ABOS) has gone down by -9.09% for the week, with a -19.63% drop in the past month and a -29.21% drop in the past quarter. The volatility ratio for the week is 7.45%, and the volatility levels for the past 30 days are 7.63% for ABOS. The simple moving average for the past 20 days is -6.71% for ABOS’s stock, with a -38.82% simple moving average for the past 200 days.
Is It Worth Investing in Acumen Pharmaceuticals Inc (NASDAQ: ABOS) Right Now?
The stock has a 36-month beta value of 0.03. Opinions on the stock are mixed, with 5 analysts rating it as a “buy,” 1 as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for ABOS is 43.86M, and at present, short sellers hold a 3.55% of that float. On January 15, 2025, the average trading volume of ABOS was 289.95K shares.
ABOS) stock’s latest price update
Acumen Pharmaceuticals Inc (NASDAQ: ABOS) has experienced a rise in its stock price by 6.64 compared to its previous closing price of 1.56. However, the company has seen a fall of -9.09% in its stock price over the last five trading days. globenewswire.com reported 2024-11-26 that NEWTON, Mass., Nov. 26, 2024 (GLOBE NEWSWIRE) — Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets toxic soluble amyloid beta oligomers for the treatment of Alzheimer’s disease, announced today that management will participate in a fireside chat at the 7th Annual Evercore ISI HealthCONx Conference on Tuesday, Dec. 3, 2024, at 3:00 p.m. ET.
Analysts’ Opinion of ABOS
Many brokerage firms have already submitted their reports for ABOS stocks, with Citigroup repeating the rating for ABOS by listing it as a “Buy.” The predicted price for ABOS in the upcoming period, according to Citigroup is $7 based on the research report published on July 26, 2024 of the previous year 2024.
Deutsche Bank, on the other hand, stated in their research note that they expect to see ABOS reach a price target of $8. The rating they have provided for ABOS stocks is “Buy” according to the report published on December 12th, 2023.
BofA Securities gave a rating of “Buy” to ABOS, setting the target price at $14 in the report published on July 20th of the previous year.
ABOS Trading at -24.52% from the 50-Day Moving Average
After a stumble in the market that brought ABOS to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -67.32% of loss for the given period.
Volatility was left at 7.63%, however, over the last 30 days, the volatility rate increased by 7.45%, as shares sank -18.67% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -42.67% lower at present.
During the last 5 trading sessions, ABOS fell by -9.78%, which changed the moving average for the period of 200-days by -59.23% in comparison to the 20-day moving average, which settled at $1.7825. In addition, Acumen Pharmaceuticals Inc saw -3.28% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at ABOS starting from OConnell Daniel Joseph, who sale 47,778 shares at the price of $1.84 back on Jan 03 ’25. After this action, OConnell Daniel Joseph now owns 454,707 shares of Acumen Pharmaceuticals Inc, valued at $87,873 using the latest closing price.
Meisner Derek M, the Chief Legal Officer & Corp Sec of Acumen Pharmaceuticals Inc, sale 11,122 shares at $1.84 during a trade that took place back on Jan 03 ’25, which means that Meisner Derek M is holding 97,745 shares at $20,506 based on the most recent closing price.
Stock Fundamentals for ABOS
Current profitability levels for the company are sitting at:
- -320.37 for the present operating margin
- 0.56 for the gross margin
The net margin for Acumen Pharmaceuticals Inc stands at -281.63. The total capital return value is set at -0.38. Equity return is now at value -32.83, with -29.52 for asset returns.
Based on Acumen Pharmaceuticals Inc (ABOS), the company’s capital structure generated 0.12 points at debt to capital in total, while cash flow to debt ratio is standing at -2.24. The debt to equity ratio resting at 0.14. The interest coverage ratio of the stock is -25.72.
Currently, EBITDA for the company is -51.61 million with net debt to EBITDA at 0.04. When we switch over and look at the enterprise to sales, we see a ratio of 341.17. The liquidity ratio also appears to be rather interesting for investors as it stands at 10.43.
Conclusion
To sum up, Acumen Pharmaceuticals Inc (ABOS) has seen a bad performance recently. Analysts have differing views on the stock, with some seeing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
